Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model

Cancer Gene Therapy

Volumn 8, Issue 5, 2001, Pages 371-377

  Hess, Stephen D ^a   Egilmez, Nejat K ^a   Shiroko, Junko ^b   Bankert, Richard B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Takayama Red Cross Hospital   (Japan)

Author keywords

Cancer immunotherapy; Human; Interleukin 12; SCID mouse; Tumor

Indexed keywords

INTERLEUKIN 12;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DNA MODIFICATION; GAMMA RADIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKOCYTES; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; PLASMIDS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034922050     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700314     Document Type: Article

References (24)

1. Cancer gene therapy: Connecting basic research with clinical inquiry
2. Gene-based strategies for the immunotherapy of cancer
3. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
4. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
5. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
6. Gene therapy with cytokine transfected xenogenic cells (vero-IL-2) in patients with metastatic solid tumors: Mechanism(s) of elimination of the transgene-carrying cells
7. Immunotherapy I: Cytokine gene transfer strategies
8. Immunotherapy of cancer with genetically modified tumor vaccines
9. Antitumor immune response of human peripheral blood lymphocytes co-engrafted with tumor into severe combined immunodeficient mice
10. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin-2 receptor β chain monoclonal antibody in mice
11. Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that is dependent upon and augmented by IL-12
12. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
13. A universal granulocyte-macrophage colony-stimulating factor producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines
14. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
15. Cancer vaccines: The interleukin-2 dosage effect
16. Interleukin-12 enhances cellular immune responses to vaccination only after a period of suppression
17. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model
18. Human-mouse lymphoid chimeras: Host-vs.-graft and graft-vs.-host reactions
19. A comparison of efficacy and specificity of three NK-depleting antibodies
20. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies
21. Human mature T cells that ate anergic in vivo prevail in SCID mice reconstituted with human peripheral blood
22. Uncoupling IL-2 signals that regulate T-cell proliferation, survival, and Fas-mediated activation-induced cell death
23. Immune suppression by recombinant interleukin (rIL)-12 involves interferon-g induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
24. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity